PT - JOURNAL ARTICLE AU - Marina Petrovic AU - Ivan Cekerevac AU - Zorica Lazic AU - Vladimir Zdravkovic TI - Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients DP - 2013 Sep 01 TA - European Respiratory Journal PG - P2916 VI - 42 IP - Suppl 57 4099 - http://erj.ersjournals.com/content/42/Suppl_57/P2916.short 4100 - http://erj.ersjournals.com/content/42/Suppl_57/P2916.full SO - Eur Respir J2013 Sep 01; 42 AB - Introduction: IL-10 serum levels were measured before chemotherapy, on completion of therapy, and at follow-up by means of a commercially available enzyme-linked immunoassay. Methods: Sixty consecutive patients,stage III or IV NSCLC undergoing conventional platinum-based regimens.Results: Elevated levels of serum IL-10 were found in cancer patients with respect to healthy control subjects (15.2 vs 7.2 pg/mL; p < 0.05), with patients with metastatic disease showing significantly higher levels than patients with undisseminated cancer (19.4 vs 12.1 pg/mL; p < 0.05). Following completion of treatment, patients were classified as responders and nonresponders. Retrospective analysis of basal IL-10 serum levels in these two subgroups showed a significant difference between responders and nonresponders (11.2 vs 19.1 pg/mL; p < 0.05). Moreover, a further significant increase in IL-10 serum levels was observed in nonresponders at the end of therapy (19.1 vs 25.6 pg/mL, prechemotherapy and postchemotherapy; p < 0.05), whereas values in responders were found to have significantly decreased (11.2 vs 10.1 pg/mL, prechemotherapy and postchemotherapy; p < 0.05). Stepwise regression analysis identified IL-10 serum level and stage as the prognostic factors related to OS, and IL-10 serum level and performance status as the prognostic factors related to TTF.Conclusions: In conclusion, this study shows that the measurement of pretreatment IL-10 serum levels is of independent prognostic utility in patients with NSCLC and may be useful for detection of disease progression.